We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TherapeuticsMD's Rejoice Study Data Published in Journal
Read MoreHide Full Article
TherapeuticsMD, Inc. (TXMD - Free Report) announced the publication of two manuscripts detailing with the results of the company’s pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
TherapeuticsMD’s share price has declined 27.3% in the past one year, while the Zacks classified Medical-Drugs industry declined 10.3%.
The randomized, controlled phase III study was conducted to evaluate the safety and efficacy of one of its lead pipeline candidate, TX-004HR, in postmenopausal women suffering from moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA). The study assessed the effect of three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) compared to placebo from baseline to week 12.
Both the manuscripts reviewed the positive TX-004HR data across all pre-specified primary and secondary endpoints in the study, along with data from a pharmacokinetic sub-study illustrating the low systemic absorption of TX-004HR. The candidate was found to be well-tolerated with a favorable safety profile. No clinically significant differences in adverse events were observed between treatment and placebo groups.
We note that TX-004HR is currently FDA review with a response expected by May 7, 2017. Approval would be a big boost for the company. According to the press release issued by the company, an estimated 32 million women are currently suffering from symptoms of VVA in the U.S., and only 2.3 million (7%) are presently being treated with prescription therapy.
TherapeuticsMD currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals, Inc. , Epizyme, Inc. and Kite Pharma, Inc. . While Sucampo sports a Zacks Rank#1 (Strong Buy), Epizyme and Kite Pharma hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016, but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.55%.
Kite Pharma’s loss estimates narrowed 2.1% and 0.2% in 2016 and 2017, respectively over last 60 days. The company posted a positive surprise in two of the four trailing quarters, with an average beat of 7.89%.
Epizyme’s loss estimates narrowed 3% and 2.4% in 2016 and 2017, respectively over last 60 days. The company posted a positive surprise in the trailing four quarters, with an average beat of 14.03%. Its share price was up 11.9% in the past one year.
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TherapeuticsMD's Rejoice Study Data Published in Journal
TherapeuticsMD, Inc. (TXMD - Free Report) announced the publication of two manuscripts detailing with the results of the company’s pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
TherapeuticsMD’s share price has declined 27.3% in the past one year, while the Zacks classified Medical-Drugs industry declined 10.3%.
The randomized, controlled phase III study was conducted to evaluate the safety and efficacy of one of its lead pipeline candidate, TX-004HR, in postmenopausal women suffering from moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA). The study assessed the effect of three doses of TX-004HR (4 mcg, 10 mcg and 25 mcg) compared to placebo from baseline to week 12.
Both the manuscripts reviewed the positive TX-004HR data across all pre-specified primary and secondary endpoints in the study, along with data from a pharmacokinetic sub-study illustrating the low systemic absorption of TX-004HR. The candidate was found to be well-tolerated with a favorable safety profile. No clinically significant differences in adverse events were observed between treatment and placebo groups.
We note that TX-004HR is currently FDA review with a response expected by May 7, 2017. Approval would be a big boost for the company.
According to the press release issued by the company, an estimated 32 million women are currently suffering from symptoms of VVA in the U.S., and only 2.3 million (7%) are presently being treated with prescription therapy.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. Price | TherapeuticsMD, Inc. Quote
Zacks Rank & Key Picks
TherapeuticsMD currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals, Inc. , Epizyme, Inc. and Kite Pharma, Inc. . While Sucampo sports a Zacks Rank#1 (Strong Buy), Epizyme and Kite Pharma hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016, but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.55%.
Kite Pharma’s loss estimates narrowed 2.1% and 0.2% in 2016 and 2017, respectively over last 60 days. The company posted a positive surprise in two of the four trailing quarters, with an average beat of 7.89%.
Epizyme’s loss estimates narrowed 3% and 2.4% in 2016 and 2017, respectively over last 60 days. The company posted a positive surprise in the trailing four quarters, with an average beat of 14.03%. Its share price was up 11.9% in the past one year.
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>